<DOC>
	<DOC>NCT02248181</DOC>
	<brief_summary>Study to document pramipexole dosing during monotherapy, occurrence of fluctuations and dyskinesias, dose increases after deterioration of Parkinson's disease (PD) symptoms, assessment of the reasons for add-on treatment with L-Dopa and dosing of pramipexole and L-Dopa when given concomitantly.</brief_summary>
	<brief_title>Post Marketing Surveillance Study of SifrolÂ® in Patients With Idiopathic Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Diagnosis of early stage idiopathic Parkinson's Disease No pretreatment with any dopaminergic treatment (de novo patients), or Pretreatment with LDopa at doses of &lt; 200 mg/d Treating physicians are asked to consider the regulation described in the Summary of Product Characteristics (SmPC) for the treatment with pramipexole</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>